This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why.

Core Insights - Zimmer Biomet, a manufacturer of knee and hip replacements, reported quarterly sales that fell short of estimates and has revised down the upper limit of its full-year organic revenue growth outlook [1] Company Summary - The company missed quarterly sales estimates, indicating potential challenges in meeting market expectations [1] - Zimmer Biomet has lowered the top end of its outlook for full-year organic revenue growth, suggesting a more conservative approach to future revenue projections [1]